Thank you, Mr. Chair and members of the committee, for the opportunity to appear before you today. Health Canada welcomes the opportunity to participate in the study of Bill C‑224 to provide context on Canada's regulatory framework for natural health products, or NHPs.
Canada's NHP sector is vibrant and innovative, contributing over $13 billion annually to the Canadian economy. It includes a broad range of participants, from small, Canadian-owned retailers to manufacturers, distributors and importers, many of which operate internationally.
Health Canada is committed to ensuring that NHPs available to Canadians are safe and effective, and of high quality. We play a critical role in protecting Canadians by regulating products used daily to improve and maintain health, including probiotics, herbal remedies, vitamins and minerals, homeopathic medicines, traditional medicines, and other products such as amino acids and essential fatty acids.
While natural health products are often perceived as lower risk, they are not without risk and require measured oversight. From experience, we know that harm may arise from undeclared ingredients, contaminants, inaccurate labelling, inappropriate use or interactions with other health products, such as pharmaceuticals. Where risks are identified, our objective is to act proportionally and consistently to protect Canadians.
Canada is an international leader in NHP regulations. We are among the few that regulate these products as health products rather than food supplements. That allows NHPs to make health claims, which uniquely enhances their appeal in both domestic and international markets. This approach appropriately reflects their lower risk profile while recognizing their health benefits.
Health Canada's role is to regulate activities such as the sale, manufacturing, packaging, labelling and importing of NHPs across the spectrum of the market to ensure the products Canadians buy are safe, effective and of high quality.
The recognition that NHPs are distinct from other drugs is central to Bill C-224. It is a principle shared by Health Canada. The bill seeks to amend legislation passed in 2023 that extends postmarket authorities to NHPs by including them in the definition of therapeutic products. The 2023 legislative change did not replace the NHP framework with a prescription drug regime. Rather, it conferred on the Minister of Health new postmarket authorities, known as Vanessa's Law authorities, with respect to NHPs. These postmarket authorities enable Health Canada to take swift action when an NHP presents a serious risk to health, which is consistent with other products we regulate. This includes the ability to order recalls and to ensure courts can impose deterrents comparable to those in the Criminal Code.
At this pivotal moment, the government is focused on supporting Canadian business, including reducing unnecessary regulatory burden. In support of this objective, Health Canada is advancing a plan for a simplified registration process for certain NHPs, more flexible labelling and reduced premarket requirements where postmarket oversight is better suited.
The committee should be aware that several of the authorities introduced in 2023 also support the reduction of regulatory red tape. This includes the ability to incorporate documents by reference, which will support the proposed registration scheme and enable flexibilities around digital labelling. It also includes the authority to grant targeted exemptions. One example is the exemption order issued by the Minister of Health in 2025, which extended the compliance timelines for new NHP labelling requirements. This measure is widely supported by natural product stakeholders and provides important flexibility for industry and time to work with Health Canada to address implementation challenges while continuing to support consumer safety.
In closing, effective regulatory tools protect consumers by helping to ensure health products remain safe, and support businesses by maintaining confidence in the marketplace. Health Canada remains committed to reducing unnecessary burden and improving processes while upholding safety.
Thank you, Mr. Chair.